AJNR Am J Neuroradiol

1. YAMAMOTO T, Lacheret C, Fukutomi H, Kamraoui RA, et al
   Validation of a Denoising Method Using Deep Learning-Based Reconstruction to Quantify Multiple Sclerosis Lesion Load on Fast FLAIR Imaging.
   AJNR Am J Neuroradiol. 2022 Jul 28. pii: ajnr.A7589. doi: 10.3174/ajnr.A7589.
   

   >> Share

   
   

   
   BMC Neurol

2. SMYTH P, Watson KE, Al Hamarneh YN, Tsuyuki RT, et al
   The effect of nurse practitioner (NP-led) care on health-related quality of life in people with multiple sclerosis - a randomized trial.
   BMC Neurol. 2022;22:275.
   

   >> Share

   
   

   
   BMJ

3. DYER O
   Multiple sclerosis: Biogen to settle claims it bribed doctors to prescribe drugs, with over $200m going to whistleblower.
   BMJ. 2022;378:o1855.
   

   >> Share

   
   

   
   J Neurol

4. CAPUANO R, Altieri M, Conte M, Bisecco A, et al
   Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod.
   J Neurol. 2022 Jul 26. pii: 10.1007/s00415-022-11296.
   

   >> Share

   
   

   
   J Neurol Neurosurg Psychiatry

5. LASLETT LL, Honan C, Turner JA, Dagnew B, et al
   Poor sleep and multiple sclerosis: associations with symptoms of multiple sclerosis and quality of life.
   J Neurol Neurosurg Psychiatry. 2022 Jul 27. pii: jnnp-2022-329227.
   

   >> Share

   
   
6. ROD BE, Torkildsen O, Myhr KM, Bo L, et al
   Safety of breast feeding during rituximab treatment in multiple sclerosis.
   J Neurol Neurosurg Psychiatry. 2022 Jul 25. pii: jnnp-2022-329545.
   

   >> Share

   
   

   
   Mult Scler

7. ZHONG M, van der Walt A, Monif M, Hodgkinson S, et al
   Prediction of relapse activity when switching to cladribine for multiple sclerosis.
   Mult Scler. 2022 Jul 27:13524585221111677. doi: 10.1177/13524585221111677.
   

   >> Share

   
   
8. MCGINLEY MP, Lapin B
   The value of patient-reported outcome measures for multiple sclerosis.
   Mult Scler. 2022;28:1489-1490.
   

   >> Share

   
   
9. STRIJBIS EM, Repovic P, Mostert J, Bowen JD, et al
   The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.
   Mult Scler. 2022;28:1606-1619.
   

   >> Share

   
   
10. KLISTORNER S, Barnett MH, Graham SL, Wang C, et al
    The expansion and severity of chronic MS lesions follows a periventricular gradient.
    Mult Scler. 2022;28:1504-1514.
    

    >> Share

    
    
11. XIANG B, Brier MR, Kanthamneni M, Wen J, et al
    Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
    Mult Scler. 2022;28:1515-1525.
    

    >> Share

    
    
12. THEBAULT S, Bose G, Booth R, Freedman MS, et al
    Serum neurofilament light in MS: The first true blood-based biomarker?
    Mult Scler. 2022;28:1491-1497.
    

    >> Share

    
    

    
    PLoS One

13. VITTURI BK, Rahmani A, Dini G, Montecucco A, et al
    Spatial and temporal distribution of the prevalence of unemployment and early retirement in people with multiple sclerosis: A systematic review with meta-analysis.
    PLoS One. 2022;17:e0272156.
    

    >> Share

    
    
14. TU H, Li N, Liu W, Fan Z, et al
    Effects of transcutaneous tibial nerve stimulation on females with overactive bladder syndrome in multiple sclerosis a protocol for a systematic review and meta-analysis.
    PLoS One. 2022;17:e0269371.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

15. DIEBOLD M, Galli E, Kopf A, Sanderson NSR, et al
    High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis.
    Proc Natl Acad Sci U S A. 2022;119:e2205042119.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share